Format

Send to

Choose Destination
See comment in PubMed Commons below
J Crohns Colitis. 2017 Jan;11(1):26-34. doi: 10.1093/ecco-jcc/jjw198. Epub 2016 Dec 7.

ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.

Author information

1
ECCO Governing Board; IBD Center, Humanitas Research Hospital, Rozzano, Milan, Italy sdanese@hotmail.com.
2
Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy.
3
ECCO GuiCom; IBD Center, Humanitas Research Hospital, Rozzano, Milan, Italy.
4
Y-ECCO; Department of Medicine, University of Cambridge, Cambridge, UK.
5
ECCO ClinCom; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
6
N-ECCO; University of Manchester/Manchester Royal Infirmary, School for Nursing/Gastroenterology, Manchester, UK.
7
P-ECCO; Department of Gastroenterology, Hepatology, Feeding Disorders and Peadiatrics, Children's Memorial Health Institute, Warsaw, Poland.
8
ECCO EduCom; 1st Department of Medicine, Semmelweis University, Budapest, Hungary.
9
ECCO Governing Board; Department of Gastroenterology, Evangelismos Hospital, Athens, Greece.
10
ECCO SciCom; Department of Gastroenterology & Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands.
11
ECCO Governing Board; University Hospital ClĂ­nic de Barcelona, Barcelona, Spain.
12
ECCO Governing Board; Gastroenterology and Inserm U954, University Hospital of Nancy, Nancy, France.
PMID:
27927718
DOI:
10.1093/ecco-jcc/jjw198
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center